Effects of activation or inhibition of preBötC SST neurons on sigh generation.
(a-d) Optogenetic activation of SST neurons generates sighs after blockade of NMBRs and GRPRs. a, Top: Schematic of the genetic strategy to target preBötC SST neurons. Bottom: Schematic depicting bilateral placement of optical cannula targeting preBötC. b, Ectopic sigh (red arrowhead) elicited by bilateral SPP (gray box) of preBötC SST neurons. c, VT (t4 = 0.176, p = 0.863), TI (t4 = 1.355, p = 0.200), TE(t4 = 0.734, p = 0.477) of ectopic sighs before blockade or VT (t4 = 0.856, p = 0.409), TI (t4 = 0.894, p = 0.389) of ectopic sighs after blockade of NMBR and GRPR were no different from endogenous sighs (n = 5 mice). TE of ectopic sighs elicited after blockade was longer than that of endogenous sighs (t4 = 4.960, p = 3 x 10-4). VT, TI, and TE of ectopic sighs before; VT: t4 = 7.925, p = 4 x 10-6; TI: t4 = 11.194, p = 10-7; TE: t4 = 5.405, p = 10-4) or after (VT: t4 = 7.245, p = 10-5; TI: t4 = 13.442, p = 10-8; TE: t4 = 9.631, p = 5 x 10-7) blockade were increased compared with eupneic breaths (n = 5 mice), indicative of augmented breaths with postsigh apneas. Statistical significance was determined with a One Way RM ANOVA followed by All Pairwise Multiple Comparison Procedures (Holm-Sidak method), VT: F3,16 = 30.357, p < 0.001; TI: F3,16 = 78.526, p < 0.001; TE: F3,16 = 31.134, p < 0.001. d, SPP elicits sighs in the presence of GRPR antagonist RC3095 and NMBR antagonist BIM23042. (e-f) Chemogenetic activation of SST neurons generated sighs after blockade of NMBRs and GRPRs. e, Top: schematic diagram of genetic strategy to selectively express DREADD receptor hM3Dq on preBötC SST neurons. Bottom: representative trace of airflow and VT during baseline, after application of CNO, and after microinjection of RC3095 and BIM23042. f, Top: Activation of hM3Dq receptors expressed on preBötC SST+ neurons significantly decreased breathing f, increases VT, and elevated sigh frequency; subsequent BIM23042 and RC3095 (B+R) microinjection into preBötC did not significantly affect breathing f, VT, nor sigh rate induced by CNO application (repeated measures ANOVA, n = 3 mice; f: F2,4 = 28.3, p = 0.004; VT: F2,4 = 25.7, p = 0.005; sigh rate: F2,4 = 26.1, p = 0.005). Bottom: representative trace depicting sighs during baseline, after application of CNO and after microinjection of NMBR and GRPR antagonists RC3095 and BIM23042. g, Top: schematic diagram of genetic strategy to selectively express ultrapotent inhibitory DREADD receptor PSAM4-GlyR on preBötC SST+ neurons. Bottom: representative trace of airflow and VT during baseline, after preBötC microinjection of peptides NMB and GRP (250 µM each, 50nl/side), and application of uPSEM817 (10mM, 30µl applied to brainstem surface). h, Top: Microinjection of peptides NMB and GRP into preBötC significantly decreased breathing f, increased VT, and elevated sigh frequency; subsequent inhibition of SST+ preBötC neurons selectively eliminated any sighs, but preserves decreased f and VT (repeated measures ANOVA, n = 3 mice; f: F2,4 = 55.8, p = 0.001; VT: F2,4 = 19.0, p = 0.009; sigh rate: F2,4 = 83.8, p < 0.001). Bottom: representative trace depicting sighs during baseline, after bilateral preBötC microinjection of NMB and GRP and after application of PSAM4-GlyR ligand uPSEM817 to the brainstem surface. Data are shown as mean ± SE. Asterisks indicate post-hoc multiple comparison test or paired t-test results: *, significance with p < 0.05; **, significance with p < 0.01.